Matches in SemOpenAlex for { <https://semopenalex.org/work/W2810134757> ?p ?o ?g. }
Showing items 1 to 99 of
99
with 100 items per page.
- W2810134757 abstract "4108 Background: The efficacy and safety of gemcitabine + erlotinib has not yet been defined prospectively in patients (pts) with metastatic pancreatic cancer (mPC) selected according to the inclusion criteria defined by Conroy et al. for FOLFIRINOX (e. g. ECOG 0-1, age < 75, bilirubin < 1.5xULN). Methods: In this German phase II trial, 150 pts with histologically confirmed mPC were recruited between July 2012 and July 2015 in 20 centers. If pts showed skin rash of any grade within 4 weeks after start of treatment with gemcitabine (1000 mg/m 2 weekly) and erlotinib (100 mg daily), this regimen was continued; rash-negative pts were switched to FOLFIRINOX. The primary study endpoint was the 1-year survival rate in rash-positive pts (hypothesis: ≥40%). Results: Ninety pts who were under treatment with gemcitabine + erlotinib for 4 weeks developed skin rash of any grade: the 1-year survival rate in those pts positive for skin rash was 40.0% (95%CI 29.8-50.9); median overall survival (OS) counted from day of first treatment was 10.1 months (mo) (95%CI 9.0-12.5), progression-free survival (PFS) 3.9 mo (95%CI 3.5-4.9), objective response rate (ORR) and disease control rate (DCR) were 21% and 64%, respectively. Median treatment duration with gemcitabine+erlotinib was 3.7 mo (Range 0.7-17.5). In rash-negative pts who were switched to FOLFIRINOX after 4 weeks of gemcitabine + erlotinib (n = 28) the 1-year survival rate was 46.4% (95%CI 27.5-66.1), median OS 10.6 mo (95%CI 6.6-13.6), median PFS 5.2 mo (95%CI 2.3-7.9) and the corresponding ORR and DCR rates were 29 and 54%, respectively. The rate of salvage therapy was 53% after gemcitabine+erlotinib, mostly consisting of 5-FU-based schemas (42 % 5-FU/folinic acid + irinotecan or oxaliplatin, 38% FOLFIRINOX) and 43% after FOLFIRINOX (all pts received gemcitabine, 67% in combination with nab-paclitaxel). In the Intention To Treat (ITT) population (n = 145) OS was 9.7 mon (95%CI 7.8-10.9). Conclusions: In rash-positive pts deemed fit for FOLFIRINOX first-line treatment with gemcitabine + erlotinib appears effective achieving a one-year-survival rate of 40%. Early switch to FOLFIRINOX was an effective strategy in rash-negative patients. Clinical trial information: NCT01729481." @default.
- W2810134757 created "2018-07-10" @default.
- W2810134757 creator A5005128603 @default.
- W2810134757 creator A5029807838 @default.
- W2810134757 creator A5031266401 @default.
- W2810134757 creator A5032081163 @default.
- W2810134757 creator A5035577287 @default.
- W2810134757 creator A5037754184 @default.
- W2810134757 creator A5045048264 @default.
- W2810134757 creator A5049518897 @default.
- W2810134757 creator A5053960245 @default.
- W2810134757 creator A5063940692 @default.
- W2810134757 creator A5067479478 @default.
- W2810134757 creator A5069481844 @default.
- W2810134757 creator A5070309355 @default.
- W2810134757 creator A5071888326 @default.
- W2810134757 creator A5080827480 @default.
- W2810134757 creator A5083168604 @default.
- W2810134757 creator A5090658045 @default.
- W2810134757 creator A5091422927 @default.
- W2810134757 date "2017-05-20" @default.
- W2810134757 modified "2023-10-05" @default.
- W2810134757 title "Efficacy of gemcitabine with erlotinib in rash-positive patients selected according to eligibility for FOLFIRINOX." @default.
- W2810134757 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.4108" @default.
- W2810134757 hasPublicationYear "2017" @default.
- W2810134757 type Work @default.
- W2810134757 sameAs 2810134757 @default.
- W2810134757 citedByCount "1" @default.
- W2810134757 countsByYear W28101347572018 @default.
- W2810134757 crossrefType "journal-article" @default.
- W2810134757 hasAuthorship W2810134757A5005128603 @default.
- W2810134757 hasAuthorship W2810134757A5029807838 @default.
- W2810134757 hasAuthorship W2810134757A5031266401 @default.
- W2810134757 hasAuthorship W2810134757A5032081163 @default.
- W2810134757 hasAuthorship W2810134757A5035577287 @default.
- W2810134757 hasAuthorship W2810134757A5037754184 @default.
- W2810134757 hasAuthorship W2810134757A5045048264 @default.
- W2810134757 hasAuthorship W2810134757A5049518897 @default.
- W2810134757 hasAuthorship W2810134757A5053960245 @default.
- W2810134757 hasAuthorship W2810134757A5063940692 @default.
- W2810134757 hasAuthorship W2810134757A5067479478 @default.
- W2810134757 hasAuthorship W2810134757A5069481844 @default.
- W2810134757 hasAuthorship W2810134757A5070309355 @default.
- W2810134757 hasAuthorship W2810134757A5071888326 @default.
- W2810134757 hasAuthorship W2810134757A5080827480 @default.
- W2810134757 hasAuthorship W2810134757A5083168604 @default.
- W2810134757 hasAuthorship W2810134757A5090658045 @default.
- W2810134757 hasAuthorship W2810134757A5091422927 @default.
- W2810134757 hasConcept C121608353 @default.
- W2810134757 hasConcept C126322002 @default.
- W2810134757 hasConcept C143998085 @default.
- W2810134757 hasConcept C2776694085 @default.
- W2810134757 hasConcept C2777148230 @default.
- W2810134757 hasConcept C2778087573 @default.
- W2810134757 hasConcept C2778570526 @default.
- W2810134757 hasConcept C2779438470 @default.
- W2810134757 hasConcept C2780258809 @default.
- W2810134757 hasConcept C2780259306 @default.
- W2810134757 hasConcept C526805850 @default.
- W2810134757 hasConcept C71924100 @default.
- W2810134757 hasConceptScore W2810134757C121608353 @default.
- W2810134757 hasConceptScore W2810134757C126322002 @default.
- W2810134757 hasConceptScore W2810134757C143998085 @default.
- W2810134757 hasConceptScore W2810134757C2776694085 @default.
- W2810134757 hasConceptScore W2810134757C2777148230 @default.
- W2810134757 hasConceptScore W2810134757C2778087573 @default.
- W2810134757 hasConceptScore W2810134757C2778570526 @default.
- W2810134757 hasConceptScore W2810134757C2779438470 @default.
- W2810134757 hasConceptScore W2810134757C2780258809 @default.
- W2810134757 hasConceptScore W2810134757C2780259306 @default.
- W2810134757 hasConceptScore W2810134757C526805850 @default.
- W2810134757 hasConceptScore W2810134757C71924100 @default.
- W2810134757 hasLocation W28101347571 @default.
- W2810134757 hasOpenAccess W2810134757 @default.
- W2810134757 hasPrimaryLocation W28101347571 @default.
- W2810134757 hasRelatedWork W1972362283 @default.
- W2810134757 hasRelatedWork W1986253711 @default.
- W2810134757 hasRelatedWork W2008500047 @default.
- W2810134757 hasRelatedWork W2127718637 @default.
- W2810134757 hasRelatedWork W2314059412 @default.
- W2810134757 hasRelatedWork W250264098 @default.
- W2810134757 hasRelatedWork W2589550854 @default.
- W2810134757 hasRelatedWork W2590475746 @default.
- W2810134757 hasRelatedWork W2590497992 @default.
- W2810134757 hasRelatedWork W2625974877 @default.
- W2810134757 hasRelatedWork W2766812598 @default.
- W2810134757 hasRelatedWork W2884529066 @default.
- W2810134757 hasRelatedWork W2888641869 @default.
- W2810134757 hasRelatedWork W2903623792 @default.
- W2810134757 hasRelatedWork W2978090192 @default.
- W2810134757 hasRelatedWork W2993760556 @default.
- W2810134757 hasRelatedWork W3037470754 @default.
- W2810134757 hasRelatedWork W3040813619 @default.
- W2810134757 hasRelatedWork W3045797302 @default.
- W2810134757 hasRelatedWork W3170648758 @default.
- W2810134757 isParatext "false" @default.
- W2810134757 isRetracted "false" @default.
- W2810134757 magId "2810134757" @default.
- W2810134757 workType "article" @default.